IDH1 and central nervous system cancer: Although a wide range of molecular biomarkers, most notably IDH mutations and 1p/19q integrity, have allowed for a more granular method with which to categorize glial tumors with clear prognostic implications, it is also inadequate for stratification of risk for gliomas simply according to IDH and 1p19q status (9, 28).